Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

Impact · against what's priced in

The article provides a bullish outlook on CMPS but offers no new material catalysts, as the FDA submission process and cash runway are already known. The valuation remains tied to the binary outcome of the COMP360 approval and the subsequent H1 2027 commercial launch.

CMPS+0.20

No priced-in read yet

In context

The company is proceeding with a rolling FDA submission for COMP360 and maintains a $433 million cash balance to fund operations until a projected H1 2027 launch.

Read from the article alone

• biotech
• healthcare
• CMPS
• depression
• fda
• psychedelics
• ptsd
• united kingdom

Search tags